{"id":"https://openalex.org/W3209914534","doi":"https://doi.org/10.3389/fimmu.2021.765822","title":"Clinical Immunogenicity Evaluation of Eptinezumab, a Therapeutic Humanized Monoclonal Antibody Targeting Calcitonin Gene-Related Peptide (CGRP) for the Preventive Treatment of Migraine","display_name":"Clinical Immunogenicity Evaluation of Eptinezumab, a Therapeutic Humanized Monoclonal Antibody Targeting Calcitonin Gene-Related Peptide (CGRP) for the Preventive Treatment of Migraine","publication_year":2021,"publication_date":"2021-10-25","ids":{"openalex":"https://openalex.org/W3209914534","doi":"https://doi.org/10.3389/fimmu.2021.765822","mag":"3209914534","pmid":"https://pubmed.ncbi.nlm.nih.gov/34759933","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/8573262"},"language":"en","primary_location":{"id":"doi:10.3389/fimmu.2021.765822","doi":"https://doi.org/10.3389/fimmu.2021.765822","is_oa":true,"landing_page_url":"https://doi.org/10.3389/fimmu.2021.765822","pdf_url":null,"source":{"id":"https://openalex.org/S2595292759","display_name":"Frontiers in Immunology","issn_l":"1664-3224","issn":["1664-3224"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","jufo-1","ki-jl-1","medline","norway-1","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320527","host_organization_name":"Frontiers Media","host_organization_lineage":["https://openalex.org/P4310320527"],"host_organization_lineage_names":["Frontiers Media"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Frontiers in Immunology","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","doaj","pubmed"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://doi.org/10.3389/fimmu.2021.765822","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5103450536","display_name":"Susan M. Pederson","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210150391","display_name":"Lundbeck (United States)","ror":"https://ror.org/04a2yjk98","country_code":"US","type":"company","lineage":["https://openalex.org/I133593841","https://openalex.org/I4210150391"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Susan Pederson","raw_affiliation_strings":["Lundbeck Seattle BioPharmaceuticals, Inc., Bothell, WA, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Lundbeck Seattle BioPharmaceuticals, Inc., Bothell, WA, United States","institution_ids":["https://openalex.org/I4210150391"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5102080293","display_name":"David M. Biondi","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210106072","display_name":"Alder (United States)","ror":"https://ror.org/00zqz6907","country_code":"US","type":"company","lineage":["https://openalex.org/I4210106072"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"David M. Biondi","raw_affiliation_strings":["Alder BioPharmaceuticals, Inc. (CKA Lundbeck Seattle BioPharmaceuticals, Inc.), Bothell, WA, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Alder BioPharmaceuticals, Inc. (CKA Lundbeck Seattle BioPharmaceuticals, Inc.), Bothell, WA, United States","institution_ids":["https://openalex.org/I4210106072"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Brent Allan","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210106072","display_name":"Alder (United States)","ror":"https://ror.org/00zqz6907","country_code":"US","type":"company","lineage":["https://openalex.org/I4210106072"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Brent Allan","raw_affiliation_strings":["Alder BioPharmaceuticals, Inc. (CKA Lundbeck Seattle BioPharmaceuticals, Inc.), Bothell, WA, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Alder BioPharmaceuticals, Inc. (CKA Lundbeck Seattle BioPharmaceuticals, Inc.), Bothell, WA, United States","institution_ids":["https://openalex.org/I4210106072"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5084396069","display_name":"Roger K. Cady","orcid":"https://orcid.org/0000-0003-4081-8395","observed_orcids":["https://orcid.org/0000-0003-4081-8395"]},"institutions":[{"id":"https://openalex.org/I4210150391","display_name":"Lundbeck (United States)","ror":"https://ror.org/04a2yjk98","country_code":"US","type":"company","lineage":["https://openalex.org/I133593841","https://openalex.org/I4210150391"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Roger Cady","raw_affiliation_strings":["Lundbeck Seattle BioPharmaceuticals, Inc., Bothell, WA, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Lundbeck Seattle BioPharmaceuticals, Inc., Bothell, WA, United States","institution_ids":["https://openalex.org/I4210150391"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5112009508","display_name":"Barbara A. Schaeffler","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210150391","display_name":"Lundbeck (United States)","ror":"https://ror.org/04a2yjk98","country_code":"US","type":"company","lineage":["https://openalex.org/I133593841","https://openalex.org/I4210150391"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Barbara Schaeffler","raw_affiliation_strings":["Lundbeck Seattle BioPharmaceuticals, Inc., Bothell, WA, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Lundbeck Seattle BioPharmaceuticals, Inc., Bothell, WA, United States","institution_ids":["https://openalex.org/I4210150391"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Brian Baker","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210150391","display_name":"Lundbeck (United States)","ror":"https://ror.org/04a2yjk98","country_code":"US","type":"company","lineage":["https://openalex.org/I133593841","https://openalex.org/I4210150391"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Brian Baker","raw_affiliation_strings":["Lundbeck Seattle BioPharmaceuticals, Inc., Bothell, WA, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Lundbeck Seattle BioPharmaceuticals, Inc., Bothell, WA, United States","institution_ids":["https://openalex.org/I4210150391"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5081580924","display_name":"John A Latham","orcid":"https://orcid.org/0000-0002-3034-1768","observed_orcids":["https://orcid.org/0000-0002-3034-1768"]},"institutions":[{"id":"https://openalex.org/I4210106072","display_name":"Alder (United States)","ror":"https://ror.org/00zqz6907","country_code":"US","type":"company","lineage":["https://openalex.org/I4210106072"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"John Latham","raw_affiliation_strings":["Alder BioPharmaceuticals, Inc. (CKA Lundbeck Seattle BioPharmaceuticals, Inc.), Bothell, WA, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Alder BioPharmaceuticals, Inc. (CKA Lundbeck Seattle BioPharmaceuticals, Inc.), Bothell, WA, United States","institution_ids":["https://openalex.org/I4210106072"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":["https://openalex.org/A5084396069"],"corresponding_institution_ids":["https://openalex.org/I4210150391"],"apc_list":{"value":2950,"currency":"USD","value_usd":2950},"apc_paid":{"value":2950,"currency":"USD","value_usd":2950},"fwci":0.7966,"has_fulltext":true,"cited_by_count":8,"citation_normalized_percentile":{"value":0.71844848,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":96},"biblio":{"volume":"12","issue":null,"first_page":"765822","last_page":"765822"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10498","display_name":"Migraine and Headache Studies","score":0.8105000257492065,"subfield":{"id":"https://openalex.org/subfields/2728","display_name":"Clinical Neurology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10498","display_name":"Migraine and Headache Studies","score":0.8105000257492065,"subfield":{"id":"https://openalex.org/subfields/2728","display_name":"Clinical Neurology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12255","display_name":"Biosimilars and Bioanalytical Methods","score":0.15000000596046448,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11016","display_name":"Monoclonal and Polyclonal Antibodies Research","score":0.013000000268220901,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/eptinezumab","display_name":"eptinezumab","score":0.8560000061988831},{"id":"https://openalex.org/keywords/immunogenicity","display_name":"immunogenicity","score":0.7509999871253967},{"id":"https://openalex.org/keywords/anti-drug-antibodies","display_name":"anti-drug antibodies","score":0.9509999752044678},{"id":"https://openalex.org/keywords/neutralizing-antibodies","display_name":"neutralizing antibodies","score":0.9959999918937683},{"id":"https://openalex.org/keywords/migraine-prevention","display_name":"migraine prophylaxis","score":0.8159999847412109},{"id":"https://openalex.org/keywords/calcitonin-gene-related-peptide","display_name":"calcitonin gene-related peptide","score":0.9549999833106995},{"id":"https://openalex.org/keywords/humanized-antibody","display_name":"humanized monoclonal antibody","score":0.9179999828338623},{"id":"https://openalex.org/keywords/drug-exposure","display_name":"drug exposure","score":0.4749999940395355},{"id":"https://openalex.org/keywords/treatment-emergent-adverse-events","display_name":"treatment-emergent adverse events","score":0.7839999794960022},{"id":"https://openalex.org/keywords/antibody-titer-decline","display_name":"antibody titer decline","score":0.5669999718666077},{"id":"https://openalex.org/keywords/drug-safety","display_name":"drug safety","score":0.39800000190734863},{"id":"https://openalex.org/keywords/chronic-migraine","display_name":"chronic migraine","score":0.47699999809265137},{"id":"https://openalex.org/keywords/episodic-migraine","display_name":"episodic migraine","score":0.9769999980926514},{"id":"https://openalex.org/keywords/monthly-migraine-days","display_name":"monthly migraine days","score":0.7149999737739563},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.5730000138282776},{"id":"https://openalex.org/keywords/humoral-immune-response","display_name":"humoral immune response","score":0.6700000166893005}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8342443704605103},{"id":"https://openalex.org/C2780868878","wikidata":"https://www.wikidata.org/wiki/Q1660197","display_name":"Immunogenicity","level":3,"score":0.7967894077301025},{"id":"https://openalex.org/C2778541695","wikidata":"https://www.wikidata.org/wiki/Q133823","display_name":"Migraine","level":2,"score":0.7370836734771729},{"id":"https://openalex.org/C163170386","wikidata":"https://www.wikidata.org/wiki/Q419432","display_name":"Calcitonin gene-related peptide","level":4,"score":0.7148479223251343},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.6190049052238464},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.6079202890396118},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.5629291534423828},{"id":"https://openalex.org/C27081682","wikidata":"https://www.wikidata.org/wiki/Q269829","display_name":"Placebo","level":3,"score":0.5334266424179077},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.510473370552063},{"id":"https://openalex.org/C2779627488","wikidata":"https://www.wikidata.org/wiki/Q315860","display_name":"Calcitonin","level":2,"score":0.4965434670448303},{"id":"https://openalex.org/C159654299","wikidata":"https://www.wikidata.org/wiki/Q79460","display_name":"Antibody","level":2,"score":0.49384886026382446},{"id":"https://openalex.org/C2910587157","wikidata":"https://www.wikidata.org/wiki/Q133823","display_name":"Chronic Migraine","level":3,"score":0.4718320965766907},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.43670719861984253},{"id":"https://openalex.org/C2780035454","wikidata":"https://www.wikidata.org/wiki/Q8386","display_name":"Drug","level":2,"score":0.42752695083618164},{"id":"https://openalex.org/C542903549","wikidata":"https://www.wikidata.org/wiki/Q422248","display_name":"Monoclonal antibody","level":3,"score":0.4242861866950989},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.32397469878196716},{"id":"https://openalex.org/C142724271","wikidata":"https://www.wikidata.org/wiki/Q7208","display_name":"Pathology","level":1,"score":0.12404957413673401},{"id":"https://openalex.org/C118303440","wikidata":"https://www.wikidata.org/wiki/Q419968","display_name":"Neuropeptide","level":3,"score":0.07497438788414001},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.07175654172897339},{"id":"https://openalex.org/C204787440","wikidata":"https://www.wikidata.org/wiki/Q188504","display_name":"Alternative medicine","level":2,"score":0.06564643979072571}],"mesh":[{"descriptor_ui":"D000906","descriptor_name":"Antibodies","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":true},{"descriptor_ui":"D000906","descriptor_name":"Antibodies","qualifier_ui":"Q000276","qualifier_name":"immunology","is_major_topic":false},{"descriptor_ui":"D004311","descriptor_name":"Double-Blind Method","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008881","descriptor_name":"Migraine Disorders","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D008881","descriptor_name":"Migraine Disorders","qualifier_ui":"Q000276","qualifier_name":"immunology","is_major_topic":false},{"descriptor_ui":"D008881","descriptor_name":"Migraine Disorders","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D008881","descriptor_name":"Migraine Disorders","qualifier_ui":"Q000517","qualifier_name":"prevention & control","is_major_topic":true},{"descriptor_ui":"D015740","descriptor_name":"Calcitonin Gene-Related Peptide","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":true},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D061067","descriptor_name":"Antibodies, Monoclonal, Humanized","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D061067","descriptor_name":"Antibodies, Monoclonal, Humanized","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D061067","descriptor_name":"Antibodies, Monoclonal, Humanized","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D061067","descriptor_name":"Antibodies, Monoclonal, Humanized","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true}],"locations_count":5,"locations":[{"id":"doi:10.3389/fimmu.2021.765822","doi":"https://doi.org/10.3389/fimmu.2021.765822","is_oa":true,"landing_page_url":"https://doi.org/10.3389/fimmu.2021.765822","pdf_url":null,"source":{"id":"https://openalex.org/S2595292759","display_name":"Frontiers in Immunology","issn_l":"1664-3224","issn":["1664-3224"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","jufo-1","ki-jl-1","medline","norway-1","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320527","host_organization_name":"Frontiers Media","host_organization_lineage":["https://openalex.org/P4310320527"],"host_organization_lineage_names":["Frontiers Media"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Frontiers in Immunology","raw_type":"journal-article"},{"id":"pmh:oai:europepmc.org:7464081","doi":null,"is_oa":true,"landing_page_url":"http://europepmc.org/pmc/articles/PMC8573262","pdf_url":null,"source":{"id":"https://openalex.org/S4306400806","display_name":"Europe PMC (PubMed Central)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1303153112","host_organization_name":"European Bioinformatics Institute","host_organization_lineage":["https://openalex.org/I1303153112"],"host_organization_lineage_names":[],"type":"repository"},"license":"other-oa","license_id":"https://openalex.org/licenses/other-oa","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"","raw_type":"Text"},{"id":"pmh:oai:pubmedcentral.nih.gov:8573262","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/8573262","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Front Immunol","raw_type":"Text"},{"id":"pmid:34759933","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/34759933","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Frontiers in immunology","raw_type":"Clinical Trial, Phase I"},{"id":"pmh:oai:doaj.org/article:398c757e717c4a9dbe52e91ddbfd5c9d","doi":null,"is_oa":true,"landing_page_url":"https://doaj.org/article/398c757e717c4a9dbe52e91ddbfd5c9d","pdf_url":null,"source":{"id":"https://openalex.org/S4306401280","display_name":"DOAJ (DOAJ: Directory of Open Access Journals)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-sa","license_id":"https://openalex.org/licenses/cc-by-sa","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Frontiers in Immunology, Vol 12 (2021)","raw_type":"article"}],"best_oa_location":{"id":"doi:10.3389/fimmu.2021.765822","doi":"https://doi.org/10.3389/fimmu.2021.765822","is_oa":true,"landing_page_url":"https://doi.org/10.3389/fimmu.2021.765822","pdf_url":null,"source":{"id":"https://openalex.org/S2595292759","display_name":"Frontiers in Immunology","issn_l":"1664-3224","issn":["1664-3224"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","jufo-1","ki-jl-1","medline","norway-1","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320527","host_organization_name":"Frontiers Media","host_organization_lineage":["https://openalex.org/P4310320527"],"host_organization_lineage_names":["Frontiers Media"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Frontiers in Immunology","raw_type":"journal-article"},"sustainable_development_goals":[{"score":1.0,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[{"id":"https://openalex.org/F4320327918","display_name":"H. Lundbeck A/S","ror":"https://ror.org/0564cd633"}],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":18,"referenced_works":["https://openalex.org/W67149354","https://openalex.org/W2046974419","https://openalex.org/W2052951012","https://openalex.org/W2140341488","https://openalex.org/W2147810684","https://openalex.org/W2148445312","https://openalex.org/W2787266772","https://openalex.org/W2955283194","https://openalex.org/W3007053288","https://openalex.org/W3012537592","https://openalex.org/W3013502865","https://openalex.org/W3092275911","https://openalex.org/W3108476696","https://openalex.org/W3120300922","https://openalex.org/W3134813359","https://openalex.org/W3138531994","https://openalex.org/W3139841107","https://openalex.org/W3163922717"],"related_works":["https://openalex.org/W4389447130","https://openalex.org/W3120300922","https://openalex.org/W4389442202","https://openalex.org/W4392584080","https://openalex.org/W3205555899","https://openalex.org/W3111958341","https://openalex.org/W3138531994","https://openalex.org/W2955283194","https://openalex.org/W3007053288","https://openalex.org/W4283794549"],"abstract_inverted_index":{"Background:":[0],"Eptinezumab":[1],"is":[2,14],"a":[3,109,125,188],"humanized":[4],"monoclonal":[5],"antibody":[6,82],"that":[7,50],"selectively":[8],"binds":[9],"calcitonin":[10],"gene-related":[11],"peptide":[12],"and":[13,144,171,196,212,223,228,254,258,278,313,318,332,339],"indicated":[15],"for":[16,39,73,102,119,135],"the":[17,27,130,185,203,217,250,276,316,337],"preventive":[18],"treatment":[19,304],"of":[20,30,37,89,142,155,174,187,205,230,245,265,271,286,320,330,342],"migraine":[21,40,58,169],"in":[22,167,226],"adults.":[23],"This":[24],"analysis":[25],"characterizes":[26],"immunogenic":[28],"profile":[29,160],"eptinezumab":[31,38,61,194,266],"using":[32],"data":[33,44],"from":[34,47,66,87,300],"clinical":[35,219],"trials":[36,98],"prevention.":[41],"Methods:":[42],"Immunogenicity":[43],"were":[45,85,94,133,148,199,237,310],"collected":[46],"five":[48,218],"studies":[49,93,179],"included":[51,180],"2076":[52],"patients":[53],"with":[54,60,99,116,242,305,315],"episodic":[55],"or":[56,269,322],"chronic":[57],"treated":[59],"at":[62,78,129,249,261],"dose":[63,267],"levels":[64],"ranging":[65],"10":[67],"to":[68,75,104,137,150,183,193,201,208],"1000":[69],"mg,":[70],"administered":[71],"intravenously":[72],"up":[74,103,136],"4":[76],"doses":[77,285],"12-week":[79],"intervals.":[80],"Anti-drug":[81],"(ADA)":[83],"results":[84],"available":[86],"2074":[88],"these":[90,290],"patients.":[91],"Four":[92],"randomized,":[95],"double-blind,":[96],"placebo-controlled":[97],"ADA":[100,117,143,206,247,256,277,301,308,321],"monitoring":[101,118],"56":[105],"weeks;":[106],"one":[107],"was":[108],"2-year,":[110],"open-label,":[111],"phase":[112],"3":[113],"safety":[114,172,340],"study":[115],"104":[120],"weeks.":[121],"Patients":[122],"who":[123],"had":[124],"confirmed":[126],"ADA-positive":[127],"result":[128],"end-of-study":[131],"visit":[132],"monitored":[134],"6":[138],"additional":[139,284],"months.":[140],"Development":[141,329],"neutralizing":[145],"antibodies":[146],"(NAbs)":[147],"evaluated":[149],"explore":[151],"three":[152],"key":[153],"areas":[154],"potential":[156,189],"impact:":[157],"pharmacokinetic":[158],"exposure":[159],"(eptinezumab":[161],"trough":[162],"plasma":[163],"concentrations),":[164],"efficacy":[165,338],"(change":[166],"monthly":[168],"days),":[170],"(rates":[173],"treatment-emergent":[175,221],"adverse":[176],"events).":[177],"These":[178],"methods":[181],"designed":[182],"capture":[184],"dynamics":[186],"humoral":[190],"immune":[191],"response":[192],"treatment,":[195],"descriptive":[197],"analyses":[198,292],"applied":[200],"interpret":[202],"relationship":[204],"signals":[207],"drug":[209],"exposure,":[210],"efficacy,":[211],"safety.":[213],"Results:":[214],"Pooled":[215],"across":[216,239],"trials,":[220],"ADAs":[222,331],"NAbs":[224,333],"occurred":[225],"15.8":[227],"6.2%":[229],"eptinezumab-treated":[231],"patients,":[232],"respectively.":[233],"Highly":[234],"consistent":[235],"profiles":[236,309,341],"observed":[238,248,260],"all":[240],"studies,":[241],"initial":[243],"onset":[244],"detectable":[246],"week":[251,262,327],"8":[252],"measurement":[253],"maximal":[255],"frequency":[257],"titer":[259,312],"24,":[263],"regardless":[264],"level":[268],"number":[270],"doses.":[272],"After":[273],"24":[274],"weeks,":[275],"NAb":[279,323],"titers":[280],"steadily":[281],"declined":[282],"despite":[283],"eptinezumab.":[287,306,343],"Interpretation:":[288],"Collectively,":[289],"integrated":[291],"did":[293,334],"not":[294,335],"demonstrate":[295],"any":[296],"clinically":[297],"meaningful":[298],"impact":[299,336],"occurring":[302],"after":[303,326],"The":[307],"low":[311],"transient,":[314],"incidence":[317],"magnitude":[319],"responses":[324],"declining":[325],"24.":[328]},"counts_by_year":[{"year":2026,"cited_by_count":1},{"year":2025,"cited_by_count":1},{"year":2024,"cited_by_count":3},{"year":2023,"cited_by_count":2},{"year":2022,"cited_by_count":1}],"updated_date":"2026-11-07T11:25:07.637180","created_date":"2021-11-08T00:00:00"}